anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Osteosarcoma (OS) is a malignant bone tumor that commonly affects young individuals. Circular RNAs (circRNAs) are associated with OS progression. In this study, we aimed to determine the role of hsa_circ_0001480 (circ_0001480) in OS development. OS cell invasion, viability, and colony numbers were assessed via transwell, cell counting kit-8, and colony formation assays, respectively. Tumor growth in vivo was also assessed using an OS mouse model. Additionally, targeted associations among the integrin-binding sialoprotein (IBSP), microRNA (miR)-363-3p, and circ_0001480 were evaluated via RNA immunoprecipitation and dual luciferase reporter assays, whereas their expression levels in OS cells and tissues were determined via quantitative reverse transcription-polymerase chain reaction and western blotting. Loss of circ_0001480 or IBSP significantly inhibited the proliferation and invasion of OS cells, but this effect was reversed by miR-363-3p downregulation. Moreover, circ_0001480 knockdown inhibited neoplasm growth in vivo. circ_0001480 directly bound to miR-363-3p, which further modulated IBSP. Both circ_0001480 and IBSP levels were high, whereas miR-363-3p levels were low in OS cells. Furthermore, low miR-363-3p levels attenuated the suppressive effects of circ_0001480 silencing on the proliferation and invasion of OS cells; however, loss of IBSP partially reversed these effects. Overall, our findings revealed circ_0001480 an oncogenic circRNA stimulating OS progression by modulating the miR-363-3p/IBSP pathway, suggesting its potential for OS treatment.
Sensitization to Staphylococcus aureus (S. aureus) enterotoxins (SEs) A (SEA) and B (SEB) is associated with the pathogenesis of several chronic airway diseases, including asthma and chronic rhinosinusitis, but its role in chronic obstructive pulmonary disease (COPD) remains unclear. This cohort study aimed to investigate the impact of sensitization to SEs on total IgE levels, and capsaicin cough reflex sensitivity (C-CS) in COPD. This study prospectively enrolled 68 patients with COPD from the outpatient department at Nagoya City University Hospital and Shizuoka General Hospital, Japan, from June 2018 to January 2020 for posthoc analysis. Patient characteristics and biomarkers, including total IgE, and C-CS, were collected. We additionally measured and serum SEA-IgE and SEB-IgE levels for this analysis. Total IgE and SEs-IgE levels in individuals with COPD were compared to those of 20 healthy individuals. The correlation between C-CS and IgE levels was evaluated using Pearson's correlation coefficient. Multivariate analyses were used to adjust the impact on SE sensitization in total IgE levels and C-CS. The prevalence of SEs sensitization was higher in patients with COPD (23.5%, N = 16) than in healthy individuals (0%, N = 0) at a cut-off value of 0.35 UA/mL or more (p = 0.018). There was a negative correlation between total serum SEB-IgE levels and declined C-CS values. Multivariate analysis showed that SEs sensitization was associated with increased total IgE levels, and declined C-CS values. This study indicated that SEs sensitization was associated with increased IgE levels and decreased C-CS in COPD. This study was approved by the ethics committee of Nagoya City University (60-18-0012) and registered in the UMIN Clinical Trials Registry (Registry ID UMIN000032497).
The second Dutch-speaking research cluster in a stepped wedge cluster design. Family doctors will implement the Care Pathway for Primary Palliative Care and will recruit eligible patients from April 2015.
BACKGROUND: Tension pneumocephalus (PMC) is a rare and feared complication following the endonasal endoscopic approach (EEA) to skull base procedures. This is a neurosurgical emergency that requires urgent decompression to avoid catastrophic neurologic damage or death. An avoidable cause is the application of positive pressure ventilation (PPV) in EEA patients for postoperative hypoxia. Our institution implemented a hospital-wide protocol in response to this to identify and manage at-risk patients; this paper aims to identify if this protocol was effective in lowering the rates of tension PMC secondary to PPV.
RESULTS: In the 3 years following the implementation of the protocol, 110 patients underwent EEAs, from which 1 case of tension PMC (found to be not secondary to PPV) was identified. This is compared with 2 cases of tension PMC secondary to PPV over the preceding 5 years, out of 406 EEA patients. This constitutes a quantifiable reduction in PPV-related tension PMC in both standard and extended approach EEAs, signifying the effective uptake of the protocol.
CONCLUSIONS: We found no cases of tension PMC after PPV following EEA skull base surgery in our institution since the implementation of an institution-wide guideline. This underscores the utility of our simple and cost-effective preventative protocol in reducing the overall rates of tension PMC following the inadvertent postoperative application of PPV. Further research is needed to study the comparative risks and benefits of PPV in the post-EEA patient and thus inform future iterations of the protocol.
Quadrivalent Human Papillomavirus (qHPV) (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™). This is the control for the Octavalent HPV with 15 mcg ISCOMATRIX™ (IMX) / Aluminum Hydroxyphosphate Sulfate (AAHS) and Octavalent HPV with 30 mcg IMX / AAHS during Phase A.
The control group patients will perform functional active alternating movements for the upper limbs at home involving three sets with 10 repetitions and a rest interval between 1- and 2-minute. Intervention will be for 3 times a week or 6 weeks.
The filamentous bacteriophage is a common immunogenic carrier for generating anti-peptide antibodies against recombinant peptides displayed on its surface. For immunizations, peptides are displayed as fusions to either the minor coat protein, pIII, or, more commonly the major coat protein, pVIII. Phage displaying a poorly expressed malarial peptide on pVIII  were compared to phage bearing the same peptide on pIII , and to phage that were chemically coupled to a synthetic version of the peptide using the crosslinker, sulfo-succinimidyl 4-(N-maleimido-methyl)cyclohexane-1-carboxylate (sulfo-SMCC) for their ability to induce an anti-peptide Ab response in mice. We also included in this comparison the same peptide displayed as a recombinant fusion to the maltose-binding protein (MBP) of Escherichia coli, as well as the synthetic counterpart as chemically crosslinked to MBP with sulfo-SMCC. The results demonstrate that only the chemically-crosslinked conjugates elicited a strong anti-peptide antibody response by ELISA, probably due to the higher number of peptides that were displayed by the phage and MBP conjugates as compared to their recombinant counterparts.  The amount of peptide that was covalently linked to the phage was increased approximately two-fold when a lysine residue was engineered near the N-terminus of mature pVIII. The ease of chemically conjugating synthetic peptides to phage, and of modifying pVIII by genetic engineering, suggests new roles for the filamentous phage in vaccine studies.
Novel compounds of formula (I), in which R1?-R11? can be the same or different and stand for hydrogen, a straight or branched aliphatic or alicyclic C1?-C10? hydrocarbon radical, an aryl or an aryl-C1?-C4?-alkyl radical; n is zero or one, and m is zero, one or two; or R2? and R4? when taken together form a saturated aliphatic 5-, 6- or 7-membered ring which may be substituted with one or more C1?-C4?-alkyl radicals; and pharmaceutically acceptable salts and easily hydrolyzable esters thereof, methods for producing said new compounds, pharmaceutical compositions containing the new compounds, dosage units of the compositions, and methods of treating patients using said compositions and dosage units. The present compounds are valuable in the human and veterinary practice by reducing bone resorption and surprisingly also stimulating bone alkaline phosphatase. A substantial increase in bone mass is actually observed during treatment with the present compounds.
<P>PROBLEM TO BE SOLVED: To provide a gene transfer agent which can transfer a gene to a hepatocyte.  <P>SOLUTION: This gene transfer agent comprises a polymer obtained by adsorbing poly(L-lysine) to a polymer complex of nucleic acid with a polymer obtained by introducing polymer chains as substituents to an aromatic ring. The gene transfer agent, wherein the aromatic ring comprises a 5 to 8C aromatic, monoring or condensed ring. The gene transfer agent, wherein the polymer chain is a polyacrylamide-based polymer block chain or a polyacrylate-based polymer block chain. The poly(L-lysine) obtained by polymerizing seven or more lysine has directivity to heparan sulfate which is a hepatic cell receptor, and can easily invade in a hepatic cell. The branched chain is preferably obtained by introducing four to six polymer chains to a benzene ring.  <P>COPYRIGHT: (C)2008,JPO&INPIT
A method of making individual castings. In the production of individual castings, in particular in dental engineering, the casting is usually premodeled in wax. However, this casting model is very susceptible to deformation, which leads to inaccuracies in the fit of the casting. With the present method, at least a part of the casting model is built up from a photopolymerizable compound which burns leaving no residue. Advantageously, the curing is carried out, in the presence of a suitable initiator, with visible light; the basis of the compound is a photopolymerizable (meth)acrylic acid ester. In dental engineering, with the present method there is made possible in a simple manner to build up form-stable casting models for making crowns, bridges, and inlays and, particularly favorably, complicated secondary parts for removable dental appliances.
Other than the Bigliani/Flatow device, there will be no difference in treatment between those patients undergoing arthroplasty with the Bigliani / Flatow prosthesis and those who previously received other prosthesis. APatients who decide to participate in the study will complete various forms prior to surgery (The Informed Consent, Contact Information Form, Demographics Module, and standard outcomes forms such as American Shoulder and Elbow Surgeon Score form, Constant's Score form, and the Simple Shoulder Test, EuroQOL and SF-36). The patient will also complete forms postoperatively at 3-month, 6-month, 1-year, 2-year, 3-year, 4-year and 5-year intervals (American Shoulder and Elbow Surgeon Score form, Constant's Score form, Simple Shoulder Test, EuroQOL and SF-36).
Patients receive four courses of MATRix (Rituximab 2 x 375 mg/m2, HD-Methotrexate 3.5 g/m2, HD-Cytarabine 2 x 2 g/m2, Thiotepa 30 mg/m2; i.v.) as induction treatment. Response assessment with gadolinium-enhanced brain MRI (centrally reviewed) takes place after course two and four. Patient with at least PR proceed to 3rd course of MATRix after first response assessment and to HCT-ASCT (BCNU 400 mg/m2, Thiotepa 4 x 5 mg/kg; i.v.) after second response assessment. Collection of autologous stem cells is planed after the second course of MATRix.
To what degree human cognition is influenced by subliminal stimuli is a controversial empirical question. One striking example was reported by Linser and Goschke (2007): participants overestimated how much control they had over objectively uncontrollable stimuli when masked congruent primes were presented immediately before the action. Critically, however, unawareness of the masked primes was established by post hoc data selection. In our preregistered study we sought to explore these findings while adjusting prime visibility based on individual thresholds, so that each participant underwent both visible and non-visible conditions. In experiment 1, N = 39 participants engaged in a control judgement task: following the presentation of a semantic prime, they freely selected between two keys, which triggered the appearance of a colored circle. The color of the circles, however, was independent of the key-press. Subsequently, participants assessed their perceived control over the circle's color, based on their key-presses, via a rating scale that ranged from 0 % (no control) to 100 % (complete control). Contrary to Linser and Goschke (2007)'s findings, this experiment demonstrated that predictive information influenced the experience of agency only when primes were consciously processed. In experiment 2, utilizing symbolic (arrow) primes, N = 35 participants had to rate their feeling of control over the effect-stimulus' identity during a two-choice identification paradigm (i.e., they were instructed to press a key corresponding to a target stimulus; with a contingency between target and effect stimulus of 75 %/25 %). The results revealed no significant influence of subliminal priming on agency perceptions. In summary, this study implies that unconscious stimuli may not exert a substantial influence on the conscious experience of agency, underscoring the need for careful consideration of methodological aspects and experimental design's impact on observed phenomena.
PURPOSE:To provide an effective hypotensive agent high in safety, free from concern for side effects due to long-term administration, containing, as active ingredient, the protein fraction separated from the microbial aqueous extract for Lactobacillus, lactic bacteria microbial component as well as a protein. CONSTITUTION:The objective hypotensive agent containing, as active ingredient, the protein fraction separated from the microbial aqueous extract for Lactobacillus (esp. pref. Lactobacillus casei YIT 9018 strain). This fraction, which is readily soluble in water, can easily be made into any form. For the administration of the present agent, oral administration is most ensured to accomplish hypotensive effect. Dose of 5-10mg/kg at a time will be enough. Because of being virtually non-toxic, every day administration of the present agent will be further effective; thus even with reduced dose, marked hypotensive activity will be manifested.
Cardiovascular disease (CVD) is a major concern in public health globally, as well as in China, and AMI is one of the leading causes of mortality and morbidity. Remarkable variations of resources available and health system performance have been noted, however little information is available about how evidence-based therapies are incorporated appropriately into routine clinical practice in China. In addition, basic data and evidence about safety, efficacy, and effectiveness of treatment for AMI during long-term recovery is limited. Practical and applied knowledge from large unselected population is needed to guide practice and policy for quality improvement and cost reduction.

This study will enroll patients with a confirmed diagnosis of AMI consecutively in 20 tertiary hospitals and 20 secondary hospitals scattered all over China. At study entry, participants will be interviewed during their index hospitalization, to collect information about symptoms, functioning, quality of life, and medical care. Demographic characteristics, medical history, clinical features, diagnostic tests, medications, procedures, and in-hospital outcomes of patients will be abstracted from medical records by well trained professional abstractors. At 1 month, 6 month, and 12 month after discharge, participants will return to the clinic for follow up visits, a face-to-face interview will be conducted to get information about clinical events, symptoms, functioning, quality of life, and medical care during the recovery period. At 1-Month and 12-Month follow-up visit, blood and urine sample will be collected. Participants' blood samples will be stored for future biologic and genetic studies. This study will examine various real-life factors that may affect patients recovery after a heart attack, including patients' characteristics and treatment measures. Practical guidelines, quality evaluative system, and risk model for AMI patients will be established based on the findings, to improve patients outcomes in future finally.
<P>PROBLEM TO BE SOLVED: To provide a gene of nontypeable strain of Haemophilus influenzae (NTHi) and uses thereof.  <P>SOLUTION: The polynucleotide sequence of a nontypeable strain of Haemophilus influenzae (NTHi) is provided. The polypeptide encoded by the polynucleotide and uses thereof are provided. The NTHi genes which are upregulated during or in response to NTHi infection of the middle ear or the nasopharynx are provided. The use of the NTHi polynucleotide and the NTHi polypeptide includes vaccine and a method of treating and preventing NTHi-associated disorders.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Mouthwash with 225ppm sodium fluoride (NaF). Positive control.
The adaptor protein 4 (AP-4) constitutes a conserved hetero-tetrameric complex within the family of adaptor protein (AP) complex, crucial for the signal-mediated trafficking of integral membrane proteins. Mutations affecting all subunits of the AP-4 complex have been linked to autosomal-recessive cerebral palsy and a complex hereditary spastic paraparesis (HSP) phenotype. Our report details the case of a 14-year-old boy born to consanguineous parents, presenting psychomotor delay, severe intellectual disability, microcephaly, and trigonocephaly. Despite a history of febrile seizures, subsequent years were devoid of seizures, with normal EEG. Exome sequencing revealed pathogenic variants in both the AP4B1 and ERF genes. Significantly, the patient exhibited features associated with AP4B1 mutations, including distinctive traits such as cranial malformations. The ERF gene variant, linked to craniosynostosis, likely contributes to the observed trigonocephaly. This case represents the initial documentation of a concurrent mutation in the AP4B1 and ERF genes, underscoring the critical role of exome analysis in unraveling complex phenotypes. Understanding these complex genotypes offers valuable insights into broader syndromic conditions, facilitating comprehensive patient management.
The present disclosure relates to adenoviral vector comprising a transgene encoding an antigen having a T cell epitope. The vector capsid comprising a modified capsid protein having a first peptide partner. A second peptide partner is attached to the first peptide partner to provide a covalently linked peptide binding pair. The second peptide partner also being attached to an antigen, the antigen having a B cell epitope. In a preferred embodiment the transgene encoding one antigen is in the lumen of the viral capsid and the second peptide attached to the second antigen is displayed on the surface of the viral capsid. Further aspects of the invention relate to vaccines comprising said vector, its use in therapy and methods of manufacture and treatment thereof.
When children are scheduled to undergo an endoscopy, research assistants will contact the family to arrange for the Esophageal String Test (EST) to be performed within one week of the endoscopy. The string test involves swallowing a small capsule with a thin piece of string inside it. The string unravels as the capsule goes down into the stomach. The investigator would tape the end of the string to the child's cheek, leaving it there for one hour. At the end of the hour, the investigator would remove the string by gently pulling it out through the mouth. Prior to swallowing the EST, the patient will complete the PEESS form (Pediatric Eosinophilic Esophagitis Symptom Scores) to assess symptoms.

The endoscopy and Endoscopic Reference System (EREFs) and EndoFLIP will be performed. The EndoFLIP is a slender probe covered by a smooth long balloon that is passed into the esophagus and slowly expanded with a salt solution. After standard of care endoscopic visualization, the FLIP, a 16 cm probe (Crospon) will be placed transorally and positioned 3 cm distal to the lower esophageal sphincter. Esophageal cross sectional areas and intrabag pressure will be measured during stepwise distensions beginning with 5 mL and increasing to a maximum of 70mL or intrabag pressure of 50 mmHg is achieved, whichever comes first. FLIP is FDA-approved without age restriction and its use has been approved by our IRBs previously. Primary results will be reported as distensibility plateau (mm).

Endoscopic severity: Endoscopic esophageal appearances will be scored using a validated EoE scoring system (EREFS). Five features of EoE will be scored: Edema (0-1), Rings (0-3) Exudates (0-2), Furrows (0-1), Stricture (0-1). Results will be reported as an inflammatory score (edema, exudates, furrows) and fibrostenotic score (rings, stricture). Functional Luminal Imaging Probe (FLIP):
<P>PROBLEM TO BE SOLVED: To provide a means for easily and reliably preventing an accident that a sample and chart information about an alien living body are falsely recognized as a sample and chart information about the same living body when using an electric chart system in observing a sample by a microscope.  <P>SOLUTION: When a prepared specimen is set on a stage of the microscope 11, the microscope reads a two-dimensional barcode on the prepared specimen and transmits it to a terminal device 12. The terminal device 12 transmits identification information obtained by converting the two-dimensional barcode received from the microscope 11 to a server device 13. The server device 13 searches a database for chart information about a living body corresponding to the identification information received from the terminal device 12 and transmits it to the terminal device 12. The terminal device 12 displays the chart information received from the server device 13. When the prepared specimen is removed from the stage, the terminal device 12 stops displaying the chart information.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Patients with histologically proven BCC will be eligible for study enrollment. 50% itraconazole compounded in petrolatum jelly will be applied under occlusion for up to 3 to 7 days.
PPB and the associated conditions found in PPB families suggest a familial tendency to formation of tumors. The International PPB/DICER1 Registry for PPB, DICER1 and Associated Conditions study will enroll and follow participants who have the DICER1 gene mutations or conditions associated with PPB or DICER1.
A method for treating vegetative dysfunctions of hypertensive type in the children comprises the use of the sedative drugs. The patients are tested psychologically. Electroencephalography, rheoencephalography, clinostatic test, and Dopplerography of the neck-and-head blood vessels are provided. When the alterations of the psychological status and brain functions are revealed, Tenoten (dosage form for children) is provided at a dose of one tablet thrice a day. When the alterations in cerebral hemodynamics and vegetative sufficiency is revealed, Homviotesin in a complex with Homvionervin are used at a dose of one tablet thrice a day. When the alterations of the cervical hemodynamics are evident, Tripsidan is provided at a dose of quarter of a teaspoon thrice a day for two months.